Stereotaxis stock soars after FDA clearance for robotic mapping catheter

Published 28/07/2025, 13:12
© Reuters.

Investing.com -- Stereotaxis (NYSE:STXS) stock surged 12% after the company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its MAGiC Sweep catheter, the world’s first robotically navigated high-density electrophysiology mapping catheter.

The MAGiC Sweep represents a significant advancement in technology for diagnosing and treating complex arrhythmia patients. Equipped with 20 electrodes, the device facilitates rapid and detailed electroanatomical mapping of heart chambers while offering extended reach and precision through integration with Stereotaxis’ Robotic Systems.

This FDA clearance marks Stereotaxis’ first approval for an interventional catheter in nearly two decades. The company describes the catheter as having an atraumatic design that prioritizes patient safety while supporting more anatomically accurate maps by avoiding the distension caused by rigid catheters.

Dr. Roderick Tung, Chief of Cardiology at The University of Arizona College of Medicine - Phoenix, highlighted the significance of the development, noting that point-by-point mapping limitations have previously held back robotic navigation adoption in electrophysiology procedures.

Similarly, Dr. Daniel Cooper, Director of Electrophysiology Lab at Washington University, emphasized that combining high-density mapping with robotics represents "an exciting long-awaited milestone for the community of robotic electrophysiologists and the broader EP field."

David Fischel, Stereotaxis Chairman and CEO, called the FDA clearance a "pivotal moment" for the company, adding that the MAGiC Sweep is only the first of multiple robotically-steered interventional devices being developed as part of the company’s innovation strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.